Kuros Bioscience
Price
Price
CHART BY
Frequently asked questions
What is Kuros Bioscience's market capitalization?
What is the Earnings Per Share (EPS) for Kuros Bioscience?
What are the analyst ratings and target price for Kuros Bioscience's stock?
What is Kuros Bioscience's revenue over the trailing twelve months?
What is the EBITDA for Kuros Bioscience?
What is the free cash flow of Kuros Bioscience?
How many employees does Kuros Bioscience have, and what sector and industry does it belong to?
What is the free float of Kuros Bioscience's shares?
Financials
- Market Cap
- $849.37M
- EPS (TTM)
- -$0.272
- Free Float
- 26.06M
- Revenue (TTM)
- $58.84M
- EBITDA (TTM)
- -$2.58M
- Free Cashflow (TTM)
- -$3.64M
Pricing
- 1D span
- $21.49$22.69
- 52W span
- $3.584$36.13
Analyst Ratings
The price target is $21.28 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
- Employees
- 5
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- CH0325814116
- Primary Ticker
- KURN